• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and Safety of Guselkumab Maintenance Therapy Among Guselkumab Induction Week 24 Clinical Responders: Results From the Phase 3 QUASAR Maintenance Study.

出版信息

Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 10):2-3.

PMID:39896686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11784578/
Abstract
摘要

相似文献

1
Efficacy and Safety of Guselkumab Maintenance Therapy Among Guselkumab Induction Week 24 Clinical Responders: Results From the Phase 3 QUASAR Maintenance Study.古塞库单抗诱导治疗第24周临床应答者中，古塞库单抗维持治疗的疗效和安全性：3期QUASAR维持研究结果
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 10):2-3.
2
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.古塞库单抗治疗中度至重度活动性溃疡性结肠炎患者（QUASAR）：3期双盲、随机、安慰剂对照诱导和维持研究
Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17.
3
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.古塞单抗治疗中重度活动性溃疡性结肠炎患者：QUASAR 期 2b 诱导研究。
Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1.
4
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Guselkumab 治疗克罗恩病患者 48 周的疗效和安全性：来自 2 期、随机、双盲 GALAXI-1 试验的维持结果。
Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14.
5
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study.古塞库单抗皮下注射诱导和维持治疗中度至重度活动性克罗恩病患者的疗效和安全性：3期GRAVITI研究结果
Gastroenterology. 2025 Aug;169(2):308-325. doi: 10.1053/j.gastro.2025.02.033. Epub 2025 Mar 18.
6
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗治疗中重度斑块状银屑病的疗效和安全性比较：来自 III 期、双盲、安慰剂和阳性对照的 VOYAGE 2 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2.
7
The Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Maintenance Study.古塞库单抗作为中度至重度活动性溃疡性结肠炎患者维持治疗的疗效和安全性：3期QUASAR维持研究结果
Gastroenterol Hepatol (N Y). 2024 Jul;20(7 Suppl 6):8-9.
8
The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12.古塞库单抗诱导治疗中重度活动性溃疡性结肠炎患者的疗效和安全性：2b期QUASAR研究第12周结果
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):12.
9
Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.在一项随机3期研究中，古塞库单抗治疗掌跖脓疱病患者1.5年的持续疗效和安全性。
J Dermatol. 2021 Dec;48(12):1838-1853. doi: 10.1111/1346-8138.16132. Epub 2021 Aug 28.
10
Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.来自VOYAGE 1和VOYAGE 2研究的结果显示，古塞库单抗在亚洲银屑病患者中具有五年的临床反应维持率和持续一致的安全性。
Dermatol Ther (Heidelb). 2023 Nov;13(11):2721-2737. doi: 10.1007/s13555-023-01026-7. Epub 2023 Sep 26.

本文引用的文献

1
The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study.古塞库单抗诱导治疗中重度活动性溃疡性结肠炎患者的疗效和安全性：3期QUASAR诱导研究结果
Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):9-10.
2
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.古塞单抗治疗中重度活动性溃疡性结肠炎患者：QUASAR 期 2b 诱导研究。
Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1.